Lower interest rates fuel prospects for American Express in stock upgrade, along with three lease-to-own companies
By Steve Gelsi
Stephens analyst lifts credit-card giant to equal weight and upgrades Aaron's Co., Prog Holdings and Upbound Group
American Express Co. drew an upgrade to equal weight from underweight at Stephens on Tuesday as analysts weighed the potential impact of an expected drop in interest rates in 2024.
After issuing a profit warning in a December webcast, American Express Co. (AXP) appears poised to return to its historical revenue and earnings-per-share growth in 2025, said analyst Vincent Caintic.
In addition, falling interest rates "have a slight benefit" to American Express due to better funding costs for charge-card receivables without yield impacts.
Moreover, most of the revenue generated by American Express is fee-based and therefore not reduced by falling rates, he said.
"We remain worried about Amex's relative credit performance, but we think interest rates will likely benefit superprime customers more," Caintic said.
American Express's stock dipped 0.2% Tuesday.
Stephens also upgraded lease-to own companies Aaron's Co. (AAN), Prog Holdings Inc. (PRG) and Upbound Group Inc. (UPBD) to overweight from equal weight on their improved prospects in a lower-interest-rate environment.
The analyst consensus estimates for Aaron's Co.'s profit appear to be overly conservative, Stephens said. The company will get a boost from lower-than-expected operating expenses, and even if that calculation is wrong, the stock price appears to be "incredibly cheap" for the company's cash-flow generation, Caintic said.
Aaron's Co.'s stock rose by 4.7% on Tuesday.
As for Prog Holdings, the company stands out as the "safest, most conservatively underwritten of the group, with credit write-offs staying firmly within their guidance range," Caintic said.
Prog Holdings' stock rose by 0.7%.
Meanwhile, Upbound Group ranks as the first of the lease-to-own companies that Stephens expects to report positive revenue in its upcoming fourth-quarter results as a "growth play" in the group, he said.
"In addition to taking market share as higher-credit lenders tighten underwriting, Upbound has had greater success winning merchant partners with its regional retailer focus," Caintic said.
Upbound Group's stock price rose by 1.1% on Tuesday.
Stephens also downgraded America's Car-Mart Inc. (CRMT) to equal weight from overweight in the face of macroeconomic headwinds due to high car prices and tighter underwriting requirements that will likely result in lower approval rates.
America's Car-Mart's stock fell by 7% on Tuesday.
Stephens also cut its Navient Corp. (NAVI) rating to underweight from equal weight based on its conclusion that analyst estimates remain about 20% higher than where they should be.
"Fundamentally we think the business is fine, though the combination of lower interest rates and the expiration of floor income contracts will significantly dampen 2024 earnings," Caintic said.
Navient's stock fell 2.7% on Tuesday.
Also read: American Express, Mastercard, Visa draw neutral rating as Monness Crespi Hardt initiates coverage
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-02-24 1130ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks